zinc finger protein 658B (pseudogene)Genealiases: []
Q-omics provides the consensus-scored ZNF658B profile across patient tissues and cancer cell-line models. ZNF658B expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZNF658B is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, ZNF658B RNA expression shows 20,400 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, THCA, and UVM as cancer lineages where ZNF658B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF658B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF658B survival associations across molecular data types. ZNF658B RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF658B RNA expression–survival associations across cancer types. High ZNF658B expression shows unfavorable associations in UVM, but favorable associations in KIRC, BRCA, MESO, SKCM and READ. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ZNF658B RNA expression.
This table summarizes ZNF658B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for ZNF658B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF658B shows lower tumor expression in THCA, KIRC, KICH, COAD, BRCA and LUAD. The THCA box plot shows higher ZNF658B RNA expression in normal versus tumor tissue (log2 FC = −1.000, t-test p < 0.001).
This table shows molecular features associated with ZNF658B in patient tissues and cancer cell lines. In patient samples, ZNF658B shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF658B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST.
